Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia

被引：0
|
作者：
Zacholski, Kyle
Bouligny, Ian Michael
Murray, Graeme
Patel, Tilak
Doyel, Michael
Boron, Josh
Tran, Valerie
Gor, Juhi
Hang, Yiwei
Thuy Ho
Venn, Chad Michael
Alnimer, Yanal Mufeed
Wages, Nolan
Grant, Steven
Maher, Keri Renee
机构：
[1] VCU, Massey Canc Ctr, Richmond, VA USA
[2] VCU, Sch Med, Richmond, VA USA
[3] VCU, Dept Internal Med, Richmond, VA USA
[4] Virginia Commonwealth Univ, Richmond, VA USA
[5] VCU, Dept Biostat, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19051
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
    Winters, Amanda C.
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Nakic, Molly
    Tobin, Jennifer
    Chase, Stephanie
    Kaiser, Jeff
    Lyle, Lindsey
    Boggs, Chelsey
    Halsema, Keri
    Schowinsky, Jeffrey T.
    Rosser, Julie
    Ewalt, Mark D.
    Siegele, Bradford
    Rana, Vishal
    Schuster, Steven
    Abbott, Diana
    Stevens, Brett M.
    Jordan, Craig T.
    Smith, Clayton
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2019, 3 (20) : 2911 - 2919
  • [22] Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Xia, Leiming
    Tian, Wanlu
    Zhao, Yiming
    Jiang, Lingling
    Qian, Wei
    Jiang, Lei
    Ge, Ling
    Li, Jianjun
    Jin, Fengbo
    Yang, Mingzhen
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [23] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [24] Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
    Vanttinen, Ida
    Ruokoranta, Tanja
    Saad, Joseph J.
    Kytola, Sari
    Hellesoy, Monica
    Gullaksen, Stein-Erik
    Ettala, Pia-Sofia
    Pyorala, Marja
    Rimpilainen, Johanna
    Siitonen, Timo
    Wennerberg, Krister
    Gjertsen, Bjorn T.
    Heckman, Caroline A.
    Kontro, Mika
    Kuusanmaki, Heikki
    BLOOD, 2023, 142
  • [25] Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
    Yamamoto, Kazuhito
    Shinagawa, Atsushi
    DiNardo, Courtney D.
    Pratz, Keith W.
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Komatsu, Norio
    Nakashima, Yasuhiro
    Yoshida, Chikashi
    Fukuhara, Noriko
    Usuki, Kensuke
    Yamauchi, Takahiro
    Asada, Noboru
    Asou, Norio
    Choi, Ilseung
    Miyazaki, Yasushi
    Honda, Hideyuki
    Okubo, Sumiko
    Kurokawa, Misaki
    Zhou, Ying
    Zha, Jiuhong
    Potluri, Jalaja
    Matsumura, Itaru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 29 - 38
  • [26] Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/ refractory FLT3mut acute myeloid leukemia
    Fu, Qiang
    Wang, Yunqi
    Liu, Hongtao
    Gao, Haitao
    Sun, Wei
    Jiang, Qian
    Jiang, Hao
    Liu, Kaiyan
    Huang, Xiaojun
    Tang, Feifei
    LEUKEMIA RESEARCH, 2024, 145
  • [27] Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
    Huber, Henriette
    Tausch, Eugen
    Schneider, Christof
    Edenhofer, Simone
    von Tresckow, Julia
    Robrecht, Sandra
    Giza, Adam
    Zhang, Can
    Fuerstenau, Moritz
    Dreger, Peter
    Ritgen, Matthias
    Illmer, Thomas
    Illert, Anna Lena
    Duerig, Jan
    Boettcher, Sebastian
    Niemann, Carsten U.
    Kneba, Michael
    Al-Sawaf, Othman
    Kreuzer, Karl -Anton
    Fink, Anna -Maria
    Fischer, Kirsten
    Doehner, Hartmut
    Hallek, Michael
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    BLOOD, 2023, 142 (11) : 961 - 972
  • [28] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Li-xia Zhu
    Rong-rong Chen
    Lu-lu Wang
    Jia-nai Sun
    De Zhou
    Li Li
    Jie-jing qian
    Yi Zhang
    Hong-yan Tong
    Wen-juan Yu
    Hai-tao Meng
    Wen-yuan Mai
    Wan-zhuo Xie
    Jie Jin
    Xiu-jin Ye
    Hong-hu Zhu
    Supportive Care in Cancer, 2022, 30 : 7031 - 7038
  • [29] The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine
    Doyel, Michael
    Bouligny, Ian Michael
    Murray, Graeme
    Patel, Tilak
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Thuy Ho
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Jonas, Brian A.
    Konopleva, Marina
    Pullarkat, Vinod
    Wei, Andrew
    Kantarjian, Hagop M.
    Pigneux, Arnaud
    Recher, Christian
    Seymour, John F.
    Dunbar, Martin
    Xu, Tu
    Mabry, Mack
    Potluri, Jalaja
    Pratz, Keith
    Letai, Anthony
    BLOOD, 2017, 130
12345